Since CIP2A is an endogenous inhibitor of PP2A [9], coupled with the fact that decreased PP2A activity could accelerate pathological p-α-syn aggregation, the key feature in PD pathogenesis, it is feasible to explore the roles of CIP2A in PD. This evidence concerns the gene PTPA and Parkinson disease.